47 results about "Multivalent Vaccine" patented technology

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The present invention provides a fusion protein and an expression vector for enhancing the soluble expression of norovirus antigens. More specifically, it provides a combination of diverse genotypes of norovirus antigen proteins and RID mutations that, when norovirus antigens are used as target proteins, fold most efficiently during the formation of recombinant fusion proteins, improve the soluble expression yield of the produced fusion proteins, and enhance the assembly efficacy and homogeneity of norovirus VLPs. Furthermore, by utilizing mutational RIDs, the present invention provides a method for rapidly and in large quantities producing not only GII.4 but also other diverse genotypes of norovirus VLPs in E. coli, thereby enabling the development of VLP-based multivalent vaccines containing a wider range of genotypes.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and / or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

The invention relates to the technical field of tag peptides, and particularly discloses a tag peptide combined on the surface of corynebacterium, and the amino acid sequence of the tag peptide is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The tag peptide provided by the invention enriches the types of tag peptides bound to the surfaces of current bacteria, and corynebacterium bacteria bound with the tag peptide have wider adaptability to pH and can be compatible with the optimal activity conditions of more foreign proteins; the molecular weight of the tag peptide is only 3.5 kDa, so that the interference to the structure or function of an exogenous protein can be remarkably reduced; in addition, the tag peptide can be fused at the N end or the C end of the target protein, the binding efficiency is not affected, simultaneous display of multiple proteins is supported, and a basis is provided for multi-enzyme cascade reaction and multivalent vaccine development.

The present invention relates to improved LAMP constructs comprising cancer antigens. Specifically, improved LAMP constructs comprising specific fragments of LAMP endodomain are provided to deliver cancer antigens to immune cells for enhanced processing. These LAMP constructs are useful in the treatment of diseases, in particular hyperproliferative disorders and / or cancer. The improved LAMP constructs, when administered to a subject, allow presentation of a correctly configured three-dimensional epitope for generating an immune response. The improved LAMP constructs may be multivalent molecules, and / or may be provided as part of multivalent vaccines containing two or more LAMP constructs. The improved LAMP constructs described herein can also be used to produce antibodies when administered to non-human vertebrates.

The present disclosure relates to methods for determining potency of multivalent RNA vaccines.

The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and / or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and / or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

The invention relates to a multi-antigen component PEI lipid delivery system and an anti-avian influenza virus multivalent vaccine comprising the same, belongs to the technical field of biological medicines, and provides a delivery system consisting of PEI, squalene, cholesterol and mPEG. The preparation method comprises the following steps of: constructing mRNA (messenger ribonucleic acid) molecules and a composite vaccine antigen system consisting of prokaryotic expression purified H7N9 avian influenza NP antigen, loading the composite vaccine antigen system into a delivery system to obtain the nanoparticles with a virus-like structure, and displaying the HA protein antigen and the NP antigen in the structure of the nanoparticles in a particle form by the nanoparticles, so that the nanoparticles can be used for preparing the H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza virus. And the mRNA molecule for coding the NA antigen, which is combined with the mRNA molecule, can be delivered into a cell in a manner of fusing lipid and a cell membrane, so that the mRNA molecule can be effectively expressed to induce a body to generate specific antibody reactions aiming at HA, NA and NP, and the body can also generate specific CTL reactions aiming at HA, NA and NP of different influenza virus strain subtypes.

The invention provides a monoclonal antibody 3G1 capable of specifically recognizing CV-A5 virus and having neutralizing activity and application of the monoclonal antibody 3G1. The monoclonal antibody is prepared from a CV-A5 virus antigen immunized mouse and splenocytes of the mouse through a cell fusion technology, and amino acid sequences of three CDR regions of a heavy chain variable region of the monoclonal antibody sequentially comprise sequences as shown in SEQ ID NO.1-3; the amino acid sequences of the three CDR regions of the light chain variable region sequentially comprise sequences as shown in SEQ ID NO.4-6. The monoclonal antibody can be specifically combined with a CV-A5 virus, and is not combined with enteroviruses such as EV-A71, CV-A10, CV-A6, CV-A16 and the like. The monoclonal antibody targets conformational epitopes, has neutralizing activity, can specifically recognize CV-A5 viruses, is an ideal CV-A5 antigen detection antibody, and is beneficial to acceleration of the research and development process of hand-foot-mouth multivalent vaccines containing CV-A5 pathogens.

The invention belongs to the field of veterinary biological products, and particularly relates to an O-type foot-and-mouth disease strain containing a VP1 N133K mutation site and a construction method of the O-type foot-and-mouth disease strain. The invention provides an attenuated O-type foot and mouth disease virus mutant strain. Asparagine at the 133rd site of VP1 protein is mutated into lysine. The amino acid sequence of the mutated VP1 protein is as shown in SEQ ID NO: 2. The invention also provides a construction method of the attenuated O-type foot-and-mouth disease virus mutant strain, wherein N133K mutation is introduced by adopting a reverse genetics technology. The FMDV VP1 N133K mutant strain constructed by the method disclosed by the invention is beneficial to research on an FMDV attenuating mechanism. In addition, by reversely introducing VP1 N133K mutation, conservative epitopes can be screened or multivalent vaccines can be designed, and the cross protection capability is improved.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and / or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases caused by K. pneumoniae, P. aeruginosa, E. coli, and / or A. pleuropneumoniae, and optionally A. baumannii.

The application discloses a monoclonal antibody specifically binding to coxsackievirus A6 and application thereof. The monoclonal antibody comprises a light chain and a heavy chain, the amino acid sequence of the complementarity determining region HCDR1 of the heavy chain is shown as SEQ ID No:1, the amino acid sequence of the complementarity determining region HCDR2 of the heavy chain is shown as SEQ ID No:4, the amino acid sequence of the complementarity determining region HCDR3 of the heavy chain is shown as SEQ ID No:7, the amino acid sequence of the complementarity determining region LCDR1 of the light chain is shown as SEQ ID No:10, the amino acid sequence of the complementarity determining region LCDR2 of the light chain is shown as GTS, and the amino acid sequence of the complementarity determining region LCDR3 of the light chain is shown as SEQ ID No:13. The monoclonal antibody has good specificity and sensitivity and has a virus neutralization capacity, and shows great potential in virus identification, diagnosis, treatment and development of multivalent vaccines.

The present invention provides new canine Influenza H3N2 vaccines, including multivalent vaccines. The present invention provides an alphavirus RNA replicon particle that encodes a Canine Influenza (CIV) H3N2 hemagglutinin (HA) antigen. The present invention further provides methods of making and using the vaccines.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The invention provides a monoclonal antibody capable of specifically recognizing a CV-A5 virus and having neutralizing activity and application of the monoclonal antibody. The monoclonal antibody is prepared from a CV-A5 virus antigen immunized mouse and splenocytes of the mouse through a cell fusion technology, and amino acid sequences of three CDR regions of a heavy chain variable region of the monoclonal antibody are sequentially shown as SEQ ID NO.1-3; the amino acid sequences of the three CDR regions of the light chain variable region are sequentially as shown in SEQ ID NO.4-6. The monoclonal antibody can be specifically combined with a CV-A5 virus, and is not combined with enteroviruses such as EV-A71, CV-A10, CV-A6, CV-A16 and the like. The monoclonal antibody targets conformational epitopes, has neutralizing activity, can specifically recognize CV-A5 viruses, is an ideal CV-A5 antigen detection antibody, and is beneficial to acceleration of the research and development process of hand-foot-mouth multivalent vaccines containing CV-A5 pathogens.

The invention relates to a multivalent vaccine, in particular to a chimera multivalent vaccine based on Ercovirus type 11, 18 and 30 key epitopes as well as a preparation method and application of the chimera multivalent vaccine. According to the invention, a chimera multivalent vaccine VP1-III is also designed based on key epitopes, an E11-VP1 sequence is taken as a basis, one E18-VP1 key epitope and two E30-VP1 key epitopes are respectively inserted into the E11-VP1 sequence to obtain a chimera multivalent protein vaccine VP1-III, and the chimera multivalent protein vaccine VP1-III is taken as an immunogen to immunize a mouse to detect antibody titer and virus neutralizing capacity of antiserum. A new thought is provided for designing and preparing multivalent vaccines and detecting immunogenicity of viral vaccines.

The invention discloses a rabbit pasteurella outer membrane vesicle trivalent vaccine and a preparation method thereof, and belongs to the technical field of multivalent vaccine preparation. According to the trivalent vaccine, outer membrane vesicle extracts from rabbit A type pasteurella multocida PmA HP-18, rabbit D type pasteurella multocida PmD HP-22 and rabbit F type pasteurella multocida PmF HP-11 are taken as antigens. The outer membrane vesicle trivalent vaccine provided by the invention contains a main outer membrane structure and periplasmic protein, has no life activity and good safety, and can effectively activate an immune system and generate protective immune response. A type pasteurella multocida, D type pasteurella multocida and F type pasteurella multocida can be prevented at the same time, and the three-prevention effect is achieved through one injection.

The application discloses a non-toxic genetically engineered toxoid molecule antigen vaccine based on a protective antigen functional domain structure and a preparation method and application thereof. It is determined that botulinum toxin and tetanus toxin both have two key protective antigen molecules, i.e. a receptor binding region Hc and a light chain-transmembrane region L-HN. Based on the important role of the functional domain in immunoprotective efficacy, a non-toxic genetically engineered toxoid or chimeric toxoid multivalent vaccine molecule is designed and prepared by using a biosynthesis technology. The vaccine has two important protective antigens of biological toxins, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency genetically engineered toxoid vaccine to replace formaldehyde inactivated toxoids for biological toxin prevention. The vaccine has important protective antigens of two different biological toxins, can produce protective efficacy against a plurality of different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.

The invention discloses a novel coronal virus mucosal immune vaccine based on a non-replicating vesicular stomatitis virus vector. The vaccine is delivered through a mucosal immunization way; the vaccine can be used in new crown vaccines, and can also be used in combination with other respiratory tract infection viruses such as respiratory syncytial vaccines (RSV) and influenza. At present, preparation of respiratory mucosa vaccines, especially multivalent vaccines, from replication-deficient VSV is not reported yet. According to the invention, safety and immunogenicity evaluation is carried out on the constructed VSVMT-S2P non-replicating recombinant VSV new crown vaccine in healthy narrative golden hamster and CP immunosuppression hamster models, and the VSVMT-S2P vaccine is found to be very safe in healthy animals; and the protein is highly safe in CP immunosuppressed hamsters. The VSVMT-S2P vaccine is subjected to single inoculation in the body of the narrative golden hamster through intranasal and intramuscular injection respectively, and it is proved that the VSVMT-S2P vaccine can effectively stimulate comprehensive immune response.

The present invention describes compositions and methods for inducing an immune response against parenteral pathogenic Escherichia coli (ExPEC), thereby providing immune protection from a disease associated with ExPEC. In particular, the present invention describes compositions comprising colibacillus polysaccharide antigens O1, O2, O4, O6, O8, O15, O16, O18, O25 and O75, and further comprising conjugates covalently bound to a carrier protein of O153 or O21 or both O153 and O21, for use in the prevention of invasive ExPEC disease.

The invention relates to the technical field of preparation of tuberculosis vaccines, in particular to preparation and application of a VLP vaccine APEH + mi3 + AS01E for enhancing BCG immunity. The preparation method comprises the following steps: mixing Ag85B-mi3, PPE33-mi3, ESAT-6-mi3 and HSPX-mi3 to obtain multivalent nanoparticles, and fully emulsifying the multivalent nanoparticles and an AS01E adjuvant to obtain the VLP vaccine APEH + mi3 + AS01E. After the VLP vaccine APEH + mi3 + AS01E provided by the invention is immunized, strong Th1 type, Th2 type and Th17 type cellular immune responses are induced; after H37Rv challenge, the immune response of Th1 type, Th2 type and Th17 type cells induced by the multivalent mi3VLP vaccine is stronger than that of BCG, and the Mtb H37Rv infection resistance is slightly higher than that of BCG; the vaccine is used as a BCG reinforcing vaccine, and can effectively reinforce the short-term protective immune response of the BCG and the anti-tubercle bacillus protection effect.

In one aspect, the present application relates to immunogenic compositions comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharide and conjugates thereof. A multivalent vaccine can be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by recombinant bacteria comprising a wzz gene.

The application discloses a monoclonal antibody specifically binding to coxsackievirus A6 and application thereof. The monoclonal antibody comprises a light chain and a heavy chain, the amino acid sequence of the complementarity determining region HCDR1 of the heavy chain is shown as SEQ ID No: 2, the amino acid sequence of the complementarity determining region HCDR2 of the heavy chain is shown as SEQ ID No: 5, the amino acid sequence of the complementarity determining region HCDR3 of the heavy chain is shown as SEQ ID No: 8, the amino acid sequence of the complementarity determining region LCDR1 of the light chain is shown as SEQ ID No: 11, the amino acid sequence of the complementarity determining region LCDR2 of the light chain is AAT, and the amino acid sequence of the complementarity determining region LCDR3 of the light chain is shown as SEQ ID No: 14. The monoclonal antibody has good specificity and sensitivity and has a virus neutralization capacity, and shows great potential in virus identification, diagnosis, treatment and development of multivalent vaccines.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The present invention relates to recombinant HVT vectors expressing antigens of avian pathogens and uses thereof. In particular, the present invention provides recombinant herpesvirus comprising and expressing a turkey (HVT) vector of an antigen of an avian pathogen, compositions comprising the recombinant HVT vectors, multivalent vaccines comprising the recombinant HVT vectors and one or more wild-type viruses or recombinant vectors. The present invention also provides methods of vaccinating against multiple avian pathogens and methods of making the recombinant HVT vectors.

The invention belongs to the technical field of biology, and discloses a method for determining a multivalent antigen sequence of an anti-periodontitis red complex, which comprises the following steps: firstly, screening out key virulence factor antigens (FimA-II, RgpA, Msp and BspA) from three core pathogenic bacteria of the red complex: porphyromonas gingivalis, treponema denticola and fusisterone; then, independently cloning each antigen gene to a pUC57 cloning vector, constructing a single antigen recombinant plasmid, and avoiding intergene interference by designing a specific enzyme cutting site; and finally, through plasmid transformation, positive clone screening and double enzyme digestion verification, the plasmid quality is ensured. The obtained single antigen plasmid can be flexibly combined and used, is beneficial to subsequent multivalent vaccine development, and has the advantages of wide antigen coverage, high expression reliability, flexible construction strategy, easiness in industrialization and the like.